Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

Dr. Ailawadhi on the Results of a First-in-Human Study of Lisaftoclax in Hematologic Malignancies

September 20th 2021, 9:20pm

International Workshop on CLL

Sikander Ailawadhi, MD, discusses the results of a first-in-human, early phase 1 study of lisaftoclax in patients with hematologic malignancies.

PAK1 Emerges as a Potential Target in Ibrutinib-Resistant CLL

September 20th 2021, 8:13pm

International Workshop on CLL

A genome-wide look into changes in three-dimensional chromatin organization between ibrutinib-resistant and parental chronic lymphocytic leukemia cells illustrated the involvement of PAK1 as an oncogenic driver in CLL.

Biomarkers May Predict Outcomes Following De-Escalated Neoadjuvant T-DM1 in HR+/HER2+ Early Breast Cancer

September 20th 2021, 7:34pm

ESMO Congress

Baseline tumor immunogenicity may be associated with higher pathologic complete response rates and favorable outcomes in hormone receptor-positive, HER2-positive early stage breast cancer when comparing de-escalated neoadjuvant ado-trastuzumab emtansine with or without endocrine therapy, vs trastuzumab plus endocrine therapy.

Zanubrutinib Responses Deepen Over Time in Relapsed/Refractory CLL

September 20th 2021, 7:24pm

International Workshop on CLL

Zanubrutinib monotherapy showed a deepening of response in patients with relapsed/refractory chronic lymphocytic leukemia.

Adjuvant Atezolizumab Shows Improvement in DFS, Time to Relapse in PD-L1+ Stage II-IIIA NSCLC Subgroups

September 20th 2021, 6:50pm

ESMO Congress

Adjuvant treatment with atezolizumab led to an improvement in disease-free survival and time to locoregional and distant relapse compared with best supportive care in prespecified subgroups of PD-L1–positive patients with stage II to IIIA NSCLC, according to exploratory findings from the phase 3 IMpower010 trial.

Sunitinib Elicits Improved Efficacy Vs Placebo in Malignant Pheochromocytoma/Paragangliomas

September 20th 2021, 4:57pm

ESMO Congress

First-line sunitinib was found to improve efficacy compared with placebo in patients with malignant pheochromocytoma and paragangliomas.

TG-1701 Monotherapy or Plus Ublituximab/Umbralisib Shows Encouraging Results in Relapsed/Refractory CLL

September 20th 2021, 4:39pm

International Workshop on CLL

TG-1701, a covalently bound BTK inhibitor, used as monotherapy or in combination with umbralisib and ublituximab, demonstrated promising activity and a manageable safety profile in patients with chronic lymphocytic leukemia.

Liso-cel Plus Ibrutinib Demonstrates Tolerable Safety Profile in Relapsed/Refractory CLL/SLL

September 19th 2021, 9:10pm

International Workshop on CLL

Lisocabtagene maraleucel in combination with ibrutinib was associated with manageable safety for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, according to updated data from the phase 1 TRANSCEND-CLL-004 trial.

cLOD May Provide More Accurate Evaluation of Cell-Free DNA in Multi-Cancer Early Detection

September 19th 2021, 8:58pm

ESMO Congress

Clinical limit of detection may be a reasonable metric for evaluating cell-free DNA for multi-cancer early detection.

Balstilimab Plus Zalifrelimab Displays Strong Efficacy, Survival Benefits in Recurrent/Metastatic Cervical Cancer

September 19th 2021, 8:10pm

ESMO Congress

The anti-PD-1 antibody balstilimab in combination with the anti-CTLA-4 antibody zalifrelimab exhibited impressive response rates, duration of response, and overall survival in patients with previously treated recurrent/metastatic cervical cancer.

Dr. Luke on the Results of the Phase 3 KEYNOTE-716 Trial in Melanoma

September 19th 2021, 8:00pm

ESMO Congress

Jason J. Luke, MD, FACP, discusses the results of the phase 3 KEYNOTE-716 trial in high-risk stage II melanoma.

Nivolumab/Chemo Combo Sustains Clinical Benefit in Frontline Gastric/GEJ Cancer, But Nivolumab/Ipilimumab Arm Misses Mark

September 19th 2021, 7:45pm

ESMO Congress

The frontline combination of nivolumab and chemotherapy upheld its improvement in progression-free and overall survival vs chemotherapy alone with longer follow-up of patients with advanced gastric, gastroesophageal junction, or esophageal cancer, according to data from the phase 3 CheckMate-649 trial.

Tisotumab Vedotin Plus Frontline Carboplatin and Second-/Third-Line Pembrolizumab Demonstrates Notable Activity in Recurrent/Metastatic Cervical Cancer

September 19th 2021, 7:42pm

ESMO Congress

Tisotumab vedotin elicited significant responses without prohibitive toxicity in combination with carboplatin as frontline therapy, as well as in combination with pembrolizumab as second- or third-line therapy in patients with recurrent or metastatic cervical cancer.

Adagrasib Shows Impressive Activity in KRAS G12C–Mutant CRC

September 19th 2021, 7:25pm

Adagrasib alone or in combination with cetuximab elicited encouraging antitumor activity and safety in heavily pretreated patients with KRAS G12C–mutant colorectal cancer, according to findings from the phase 1/2 KRYSTAL-1 trial.

Survival Benefit Found With Abiraterone/Prednisolone-Based Combos in High-Risk Nonmetastatic Prostate Cancer

September 19th 2021, 6:57pm

ESMO Congress

When added to androgen-deprivation therapy, abiraterone acetate and prednisolone with or without enzalutamide for 2 years improved survival outcomes in men with high-risk nonmetastatic prostate cancer.

Dr. Rugo on Overall Survival With First-Line Pembrolizumab in Metastatic TNBC

September 19th 2021, 6:12pm

ESMO Congress

Hope S. Rugo, MD, discusses the overall survival data with first-line pembrolizumab plus chemotherapy as a treatment for patients with metastatic triple-negative breast cancer, as reported in the phase 3 KEYNOTE-355 trial.

Dr. Cheah on the Efficacy of TG-1701 Alone and in Combination With U2 in CLL

September 19th 2021, 6:04pm

International Workshop on CLL

Chan Cheah, MBBS, discusses the results of a study evaluating the efficacy and safety of TG-1701 alone and in combination with ublituximab and umbralisib in chronic lymphocytic leukemia.

Dr. Danilov on the Efficacy of Entospletinib Plus Obinutuzumab in Relapsed/Refractory CLL

September 19th 2021, 6:02pm

International Workshop on CLL

Alexey V. Danilov, MD, PhD, discusses the efficacy of entospletinib plus obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.

Prednisone Added to ADT Plus Docetaxel Improves Radiographic PFS and OS in mCSPC

September 19th 2021, 5:56pm

ESMO Congress

Prednisone added to androgen-deprivation therapy plus docetaxel improved radiographic progression-free survival and overall survival in patients with de novo metastatic castration-sensitive prostate cancer.

Sabizabulin Appears Safe, Effective in Metastatic Castration Resistant Prostate Cancer

September 19th 2021, 5:55pm

ESMO Congress

Sabizabulin was well tolerated and associated with significant and durable objective tumor responses in patients with metastatic castration resistant prostate cancer.